Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy
Journal of Thrombosis and Haemostasis · 2026-10
DOI: 10.1016/j.jtha.2026.10.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-10. Verfasst von Claudia Kelsch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd, Genentech Inc.
Abstract (Originalsprache)
INTRODUCTION: Thromboembolic events (TEs) and thrombotic microangiopathies (TMAs) were identified as risks in people with congenital haemophilia A (PwcHA) receiving the subcutaneous bispecific antibody emicizumab, particularly when receiving concurrent activated prothrombin complex concentrate (aPCC) at >100U/kg/24hr for ≥24hrs. Sharing long-term TE/TMA safety data is critical to inform clinical decision-making. METHODS: TE/TMA data were extracted from individual safety report sources from within the Roche Emicizumab Global Safety Database from June 2012-August 2025; events were characterised based on association with aPCC or medical devices, demographics, and cardiovascular risk factors. The non-aPCC-associated TE incidence rate from clinical trials was compared with background rates from the US-based MarketScan claims database. RESULTS: In the 13-year observation period, 165 TEs/TMAs were identified in 138 PwcHA. Two TEs and all five TMAs were associated with concomitant aPCC use at >100U/kg/24hr for ≥24hrs. Of the non-aPCC-associated TEs, 148 non-device-associated TEs were identified in 121 PwcHA (median [range] age: 56 [0.8-86.0] years); 41.3% (50/121) of these PwcHA had ≥1 pre-existing cardiovascular/thrombotic risk factor. The rate of non-aPCC-associated TEs in emicizumab clinical trials (0.36 per 100 person-years; 95% confidence interval [CI], 0.16-0.68) was comparable with the general background incidence in PwcHA (0.52 per 100 person-years; 95% CI, 0.40-0.69). CONCLUSIONS: No new safety concerns for TEs/TMAs were identified and the benefit-risk profile of emicizumab remains positive following >13 years of surveillance. Since 2023, special monitoring of TEs/TMAs is no longer required for emicizumab; however, monitoring and reporting of safety data are still ongoing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, CA, USA.
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Förderung
- F. Hoffmann-La Roche Ltd
- Genentech Inc
Zitieren
APA
Kelsch, C., Biondo, J. M. L., Niggli, M., Polito, L., & Tobaruela, G. (2026). Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.10.014
Vancouver
Kelsch C, Biondo JML, Niggli M, Polito L, Tobaruela G. Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.10.014
BibTeX
@article{Kelsch2026,
author = {Kelsch, Claudia and Biondo, Juliana M L and Niggli, Markus and Polito, Letizia and Tobaruela, Guillermo},
title = {Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2026.10.014}
}
EUVIMED